Summarizing the cell-mediated immune responses that were obtained at day 90, prior to influenza virus challenge, suggest that the used adjuvants were all capable of supporting both influenza-antigen stimulated IFN-γ secreting and IL-5 secreting immunity in vitro. This evidence concerns the gene IL5 and influenza.